According to the current Guideline on Requirements for Revision/Renewal of Certificates of Suitability to European Pharmacopoeia monographs issued by EDQM, Carelife submitted 7 annual notifications of COS dossiers to EDQM for the first time in September 2011, covering Clindamycin HCl, Clindamycin Phosphate, Mitoxantrone HCl, Granisetron HCl, Venlafaxine HCl and Alendronate Sodium, all of which have been approved by EDQM.
